Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA
November 27, 2015
Canada, along with four other countries, participated in a study comparing ClikSTAR with other pens. The results, being presented at the World Diabetes Congress, reveal that a higher proportion of patients found ClikSTAR easier to use than other comparator pens when assessed in specific categories such as replacing the cartridge, dialing a dose and hearing/feeling the clicking sound.
"It's an added bonus that the Lantus ClikSTAR was developed with patients' needs in mind," said Stacey Horodezny, a diabetes educator based at the Trillium Health Centre in Mississauga, Ontario.
"For patients, ease of use, flexibility and comfort are what matter most," she added. "For us, as nurse educators, these features are also important because they allow us to spend more time on all the other aspects of insulin and diabetes management."
In addition to Canada, the new pen is being launched in Switzerland, Greece and the Netherlands. ClikSTAR is currently being reviewed by the U.S. Food and Drug Administration.
Source: SANOFI-AVENTIS CANADA